<DOC>
	<DOCNO>NCT00111774</DOCNO>
	<brief_summary>The purpose study determine ABX-EGF safe efficacious patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Evaluating ABX-EGF Patients With Metastatic ColorectalCarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Cohort A : Pathologic diagnosis colorectal carcinoma fine needle aspiration tissue biopsy Metastatic colorectal carcinoma Must previously fail therapy fluoropyrimidine either irinotecan oxaliplatin ; may receive irinotecan oxaliplatin ; chemotherapeutic agent may give concurrently sequentially . May receive prior radiotherapy ( target lesion irradiate ) Bidimensionally measurable disease Paraffinembedded tumor tissue available immunohistochemistry ( IHC ) study epidermal growth factor receptor ( EGFr ) expression ( archived tissue acceptable ) Tumorexpressing EGFr immunohistochemistry ( stain must 2+ 3+ great equal 10 % evaluated tumor cell ; stain evaluation conduct central laboratory ) ECOG score 0 1 Adequate hematologic , renal , hepatic function Cohort B : The inclusion criterion Cohort A apply Cohort B , exception follow tumor express EGFr criterion : *Cohort B include subject IHC stain 1+ present great 10 % evaluated tumor cell , OR IHC stain sum 1+ , 2+ 3+ present great 10 % evaluated tumor cell sum 2+ 3+ present less 10 % evaluated tumor cell Cohorts A B : Female subject ( e.g. , childbearing potential , postmenopausal less 6 month , surgically sterilize abstinent ) willing use oral implanted contraceptive , double barrier birth control , intrauterine device ( IUD ) course study 6 month follow last ABXEGF infusion Female subject breast feeding positive serum pregnancy test within 72 hour prior first ABXEGF infusion Male subject willing use adequate contraception upon enrollment study 1 month follow last ABXEGF infusion Untreated brain metastasis Use systemic chemotherapy radiotherapy within 30 day prior first dose ABXEGF Chemotherapy fluoropyrimidines , irinotecan oxaliplatin colorectal carcinoma . Leucovorin levamisole consider chemotherapy exclusion criterion . Prior EGFr target agent Prior investigational drug potential antitumor activity ( experimental small molecule within 30 day prior first ABXEGF infusion , experimental proteins/antibodies within 3 month prior first ABXEGF infusion ) If prior history cancer , colorectal carcinoma , basal cell carcinoma , cervical carcinoma situ , treatment active disease within 5 year Myocardial infarction within past year Left ventricular ejection fraction ( LVEF ) less 45 % , measure multiplegated acquisition ( MUGA ) scan Known HIV positive History chronic medical psychiatric condition laboratory abnormality , opinion investigator , may increase risk associate study participation study drug administration may interfere interpretation study result Subject allergic ingredient study medication Staphylococcus Protein A Unwilling unable comply study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Colon Cancer , Rectal Cancer</keyword>
	<keyword>Colorectal Carcinoma , EGFr</keyword>
	<keyword>Metastatic Cancer , ABX-EGF</keyword>
	<keyword>Panitumumab , Abgenix</keyword>
	<keyword>Clinical Trial , Immunex , Amgen</keyword>
	<keyword>Metastatic Colorectal</keyword>
</DOC>